Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

Merck & Co. logo
Merck & Co.MRK
——
Delcath Systems logo
Delcath SystemsDCTH
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Citius Oncology, Inc. (CTOR) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $1.83 in Q3 2026.
How has Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price decreased by 0.0% year-over-year, from $1.83 to $1.83.
What is the long-term trend for Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 3 years (2023 to 2026), Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a -5.2% compound annual growth rate (CAGR), from $2.15 to $1.83.